These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19965667)

  • 1. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
    Saussele S; Lauseker M; Gratwohl A; Beelen DW; Bunjes D; Schwerdtfeger R; Kolb HJ; Ho AD; Falge C; Holler E; Schlimok G; Zander AR; Arnold R; Kanz L; Dengler R; Haferlach C; Schlegelberger B; Pfirrmann M; Müller MC; Schnittger S; Leitner A; Pletsch N; Hochhaus A; Hasford J; Hehlmann R;
    Blood; 2010 Mar; 115(10):1880-5. PubMed ID: 19965667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
    Luo Y; Zhao Y; Tan Y; Shi J; Han X; Zheng Y; Li L; He J; Xie W; Ye X; Cai Z; Lin M; Huang H
    Leuk Res; 2011 Oct; 35(10):1307-11. PubMed ID: 21354617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
    Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
    Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
    Khoury HJ; Kukreja M; Goldman JM; Wang T; Halter J; Arora M; Gupta V; Rizzieri DA; George B; Keating A; Gale RP; Marks DI; McCarthy PL; Woolfrey A; Szer J; Giralt SA; Maziarz RT; Cortes J; Horowitz MM; Lee SJ
    Bone Marrow Transplant; 2012 Jun; 47(6):810-6. PubMed ID: 21986636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
    Kantarjian HM; O'Brien S; Cortes JE; Giralt SA; Rios MB; Shan J; Giles FJ; Thomas DA; Faderl S; De Lima M; Garcia-Manero G; Champlin R; Arlinghaus R; Talpaz M
    Blood; 2002 Sep; 100(5):1590-5. PubMed ID: 12176876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
    McCann SR; Gately K; Conneally E; Lawler M
    Blood; 2003 Feb; 101(3):1200-1. PubMed ID: 12529295
    [No Abstract]   [Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.
    Bhatt VR; Akhtari M; Bociek RG; Sanmann JN; Yuan J; Dave BJ; Sanger WG; Kessinger A; Armitage JO
    J Natl Compr Canc Netw; 2014 Jul; 12(7):963-8. PubMed ID: 24994916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
    Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
    Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration.
    Sohn SK; Kim JG; Kim DH; Lee KB
    Br J Haematol; 2003 May; 121(3):469-72. PubMed ID: 12716370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
    Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
    Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.
    Jain N; van Besien K
    Hematol Oncol Clin North Am; 2011 Oct; 25(5):1025-48, vi. PubMed ID: 22054733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
    Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of imatinib mesylate for hematopoietic stem cell transplantation.
    Goldman J
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):28-34. PubMed ID: 11526599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
    Ullmann AJ; Hess G; Kolbe K; Friedrich-Freksa A; Meyer RG; Gschaidmeier H; Huber C; Fischer T
    Keio J Med; 2003 Sep; 52(3):182-8. PubMed ID: 14529151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
    Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
    Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
    Goldman J
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
    Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
    Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.